The Series B financing provides further validation of miRagen and the promise of microRNA-based therapeutics.

Terascala is a leader in the development of solutions that address this requirement, and the fact that its product runs on an open source file system and on industry-standard platforms makes for a very compelling value proposition in a price sensitive market.

MaRS today announced the creation of JOLT, a new technology accelerator dedicated to building high-growth web and mobile companies that promise to transform the way consumers and enterprises connect, work and play.

Dynamic UX/UI capabilities to enhance company’s Unifeed™ Mobile Middleware Platform appRenaissance (www. apprenaissance. com), a leading provider of mobile applications, tools and infrastructure, announced today that it has acquired UXFLIP, an innovator in dynamic mobile interface capabilities.

The Halifax Group, a private equity firm that partners with management to invest in growing entrepreneurial companies, announced today that it has sold PolyPipe Holdings, Inc. (“PolyPipe”) to Dura-Line Holdings, Inc. Terms of the sale were not disclosed.

Pacific Equity Partners (PEP) has sweetened its takeover offer for Spotless Group (SPT.AX), bringing the deal value above the A$743 million ($765 million) that the Australian business services company has been seeking, two sources with knowledge of the deal told Reuters.

Private equity firm CVC Capital Partners Ltd will buy a majority stake in AlixPartners LLP as the restructuring and consulting firm looks to develop its services and expand geographically.

Sumitomo Mitsui Financial Group will buy a 24 percent stake in a mid-sized Chinese asset management firm for around $125 million, two sources with direct knowledge of the matter said, a move that would be its first foray in China's wealth management market.

China's rigid capital rules ban its citizens from investing directly in Apple Inc but that's not keeping them from seeking a piece of the iPhone maker's success by buying shares in its suppliers - and even companies rumored to be suppliers.

The purpose is to complete the product development and market introduction of Accelr8’s BACcel™ culture-free, diagnostic system for same-shift identification and antibiotic resistance testing of bacterial and fungal pathogens.